Form 4: Elanco Director Harrington Receives Equity Award

Elanco Animal Health Inc. Director Michael J. Harrington was granted 10,314 deferred stock units as an annual equity award.

Summary

• Michael J. Harrington, a Director of Elanco Animal Health Inc. (ELAN), received an equity award.
• The transaction involved the acquisition of 10,314 shares of Common Stock.
• The transaction date was November 28, 2025.
• The acquisition price per share was $0, as it was a grant of deferred stock units.
• Following this transaction, Harrington beneficially owns 109,577 shares of Common Stock.
• This grant represents an annual equity award for non-employee members of the Issuer's Board of Directors.

Sentiment

Score: 7

Explanation: The filing indicates a routine, positive event of a director receiving an equity award, which aligns interests and is a standard compensation practice. No negative or unexpected elements are present.

Positives

• Director Michael J. Harrington received an annual equity award, aligning his interests with shareholders.
• The grant of 10,314 deferred stock units at a $0 price indicates compensation for board service.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Industry Context

This Form 4 filing details a routine equity award to a non-employee director, which is a standard practice across many industries, including animal health, to compensate board members and align their interests with long-term shareholder value. It does not provide specific insights into broader industry trends or competitive landscape.

Comparison to Industry Standards

• The grant of deferred stock units as an annual equity award to non-employee directors is a common compensation practice in publicly traded companies, including those in the animal health sector, aligning director incentives with company performance.
• Specific comparable companies, projects, or results are not detailed within this Form 4 filing to allow for a direct, granular comparison.

Stakeholder Impact

• Shareholders: The grant of equity to a director aligns their interests with shareholder value creation, potentially fostering better long-term decision-making.
• Employees: No direct impact on employees is indicated.

Key Dates

Keywords

Elanco Animal Health, ELAN, Michael J. Harrington, Director, Equity Award, Deferred Stock Units, Insider Transaction, Form 4, Stock Grant